Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors - PubMed
4 hours ago
- #genomic profiling
- #economic modeling
- #precision oncology
- Study compares whole-exome/whole-transcriptome sequencing (WES/WTS) with 50-gene panels for tumor profiling in solid tumors from a US payer perspective.
- WES/WTS testing directs more patients to targeted therapies across TNBC, CRC, NSCLC, and CRPC, with minimal changes in per-member per-month costs (range: cost-savings of $0.0517 in NSCLC to a $0.0268 increase in CRPC).
- Testing costs represent only 1.1-2.1% of total per-patient costs, with most costs driven by medical and pharmacy expenses, suggesting WES/WTS is economically feasible with potential clinical benefits.